A 54-year-old woman in Quebec died of a blood clot after receiving AstraZeneca’s Covid-19 vaccine, provincial public health chief Horacio Arruda said. It is the first such fatality in Canada.
“We just had our first patient who died of thrombosis, cerebral thrombosis, following the AstraZeneca vaccination”, Arruda said at a press conference on Tuesday.
Speaking of fate, Quebec Premier Francois Legault said yes “very sad to know that a 54 year old woman in good shape … died because she was vaccinated”.
Arruda said tests at Hamilton’s McMaster University laboratory had found antibodies that had caused a problem with the platelets in his blood, which led to his death.
Also on rt.com
Canada halts launch of AstraZeneca vaccine for people under 55, citing ‘substantial uncertainty’ amid blood clot problems
About 400,000 people have received AstraZeneca’s Vaxzevria vaccine in Quebec, Arruda said.
Three other cases of blood clotting are being studied, including one person recovering and two cases that have not been confirmed to be related to the vaccine.
Earlier this month, Canada’s first case of a blood clot in someone who was injected with Vaxzevria was also confirmed in a woman in Quebec.
A number of vaccine-related blood clotting cases had already been reported in EU countries and investigated by the blockade’s drug regulator, the European Medicines Agency (EMA).
Also on rt.com
Canadian city of Hamilton opens vaccine eligibility to people aged 18 and over in outbreak hotspots, as long as they are not WHITE
EMA lent its support to the jab after the review found unusual blood clots with low platelets are a “very rare” side effect, which is estimated to occur in 1 in 100,000 people who are vaccinated.
The regulator said that most cases of blood clotting in people who have been given Vaxzevria occur in women under the age of 60 within three weeks of vaccination.
In late March, the Canadian National Advisory Committee on Immunization (NACI) suspended jab use in people under 55 in light of rare reports of serious blood clots among Vaxzevria recipients, but subsequently revised his recommendation so that the vaccine can be given to those over 30.
Do you think your friends would be interested? Share this story!